The current status of thrombolytic therapy

Area of Science:

• Cardiology
• Emergency Medicine
• Pharmacology

Background:

• Fibrinolytic therapy is a cornerstone in reducing mortality for acute myocardial infarction (AMI).
• Effective patient selection and appropriate treatment protocols are vital for maximizing benefits and minimizing risks.
• Understanding contraindications and risk factors is essential for safe and effective fibrinolysis.

Purpose of the Study:

• To review patient selection criteria for fibrinolytic therapy in acute myocardial infarction.
• To discuss contraindications and factors influencing treatment regimen choice.
• To highlight the importance of individualized therapy based on patient-specific risks.

Main Methods:

• Review of current guidelines and clinical trial data (e.g., COBALT trial) on fibrinolytic therapy for AMI.
• Analysis of patient characteristics, including symptom onset, ECG findings, and contraindications.
• Comparison of different fibrinolytic regimens and adjunctive therapies like heparin.

Main Results:

• Fibrinolytic therapy requires patients to present within 12 hours of ischemic symptoms with ECG changes and no contraindications (e.g., recent stroke, intracranial tumor, major bleeding risk).
• Age and hypertension are not absolute contraindications but may necessitate regimen modification.
• The COBALT trial indicated the accelerated weight-related tissue plasminogen activator (t-PA) regimen is favorable, though equivalent to double bolus t-PA in patients under 75.

Conclusions:

• Individualized treatment selection for acute myocardial infarction is now recommended over a one-size-fits-all approach.
• Treatment choices should be based on a comprehensive assessment of cardiac risk, stroke risk, bleeding risk, and cost.
• Optimizing fibrinolytic therapy requires careful consideration of patient-specific factors and evolving clinical evidence.